MediWound Ltd. (MDWD)
| Market Cap | 80.11M |
| Revenue (ttm) | 24.95M |
| Net Income (ttm) | -11.12M |
| Shares Out | 27.25M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,741 |
| Open | 2.77 |
| Previous Close | 2.89 |
| Day's Range | 2.77 - 3.11 |
| 52-Week Range | 2.20 - 6.22 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 6.92 (+135.3%) |
| Earnings Date | Nov 16, 2021 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological dr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 6.92, which is an increase of 135.26% from the latest price.
News
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and ...
Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022
EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
Anticipate Submission for Label Extension in First Half 2022 Anticipate Submission for Label Extension in First Half 2022
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
MediWound Reports Third Quarter 2021 Financial Results
Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21%
Earnings Preview For MediWound
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.
MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021
YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wou...
EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar
MediWound to Present at Upcoming Investor Conferences
YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tiss...
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MediWound Reports Second Quarter Financial Results
Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...
Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin ca...
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Data Expected End of 2021
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the ...
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
Why Shares Of MediWound And Vericel Fell On Tuesday
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?